Evidence map›Paper›PMID 26253381›Full record

ReviewAutoimmunity reviews2015

IL-27-induced modulation of autoimmunity and its therapeutic potential.

Rakeshchandra R Meka, Shivaprasad H Venkatesha, Steven Dudics, Bodhraj Acharya, Kamal D Moudgil

Abstract readReview
In one paragraph

Review in Autoimmunity reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 195 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Characterization of an isogenicInfection and immunity · 2026
    Article
  4. Article
  5. Article
  6. Cytokines Associated with Activation of CD4International journal of molecular sciences · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Vaccines · 2025
    Review
  16. Review
  17. Interleukins 30 and 27 in psoriasis and inflammation.Postepy dermatologii i alergologii · 2025
    Review
  18. Article
  19. Review
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rakeshchandra R Meka *Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA.
Shivaprasad H Venkatesha *Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA.
Steven DudicsDepartment of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA.
Bodhraj AcharyaDepartment of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA.
Kamal D MoudgilDepartment of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore Street, HSF-1, Suite 380, Baltimore, MD 21201, USA.
University of Maryland, Baltimore · US

Funding

Defining glomerulus-homing peptides for targeted drug delivery in lupus nephritisR21AI109470 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI MOUDGIL, KAMAL D · 2014 to 2015
$422k
Identification of CNS-homing peptides for therapeutic use in multiple sclerosisR21NS082918 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI MOUDGIL, KAMAL D · 2013 to 2014
$420k
NIAID NIH HHS R21 AI109470NIAID NIH HHS R21AI109470NINDS NIH HHS R21 NS082918NINDS NIH HHS R21NS082918
6 · The paper itself

Abstract

Interleukin-27 (IL-27) is a new member of the IL-12 family. It is produced by activated antigen-presenting cells and plays an important role in the regulation of CD4+ T cell differentiation and immune response. IL-27 activates multiple signaling cascades, including the JAK-STAT and p38 MAPK pathways. Several studies have revealed that IL-27 promotes the differentiation of Th1 and Tr1, but inhibits Th2, Th17, and Treg cells. However, a few studies have shown an opposite effect on certain T cell subsets, such as Treg. IL-27 displays both pro- and anti- inflammatory activities in different autoimmune diseases. Here, we have discussed the role of IL-27 in rheumatoid arthritis, multiple sclerosis, colitis, lupus, psoriasis, type 1 diabetes, and uveitis. Most of this information is derived from experimental models of these autoimmune diseases. The mechanistic basis of the dual role of IL-27 in inflammation and autoimmunity is still not fully defined. In general, the pro-/anti-inflammatory activity of IL-27 is influenced by the underlying immune effector pathways, the phase of the disease, the presence or absence of counter-regulatory cytokines/T cell subsets, and the tissue/cell type under study. Despite a spectrum of outcomes in various autoimmune diseases, mostly anti-inflammatory and immunomodulatory effects of IL-27 have been observed in this category of diseases. Accordingly, IL-27 represents a novel, promising target/agent for the treatment of autoimmune diseases.

Indexed as

AutoimmunityAnimalsAntigen-Presenting CellsB-LymphocytesCD4-Positive T-LymphocytesCell DifferentiationHumansInterleukin-27Lymphocyte ActivationInterleukin-27ArthritisAutoimmunityCD4(+) T cell differentiationColitisDiabetesInterleukin-27LupusMultiple sclerosisPsoriasisUveitis

Identifiers

PMID26253381
PMCPMC4628569
OpenAlexW1070777618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.